Cognition Therapeutics, Inc. Schedules End-of-Phase 2 Meeting with FDA for Alzheimer's Treatment and Files Applications for Breakthrough Status in Dementia with Lewy Bodies
25/6 13:41
Cognition Therapeutics plans a Phase 2 meeting with FDA for zervimesine in Alzheimer's disease and submitted applications for DLB....